The United States has opened a formal Section 301 investigation into Germany’s pharmaceutical pricing and reimbursement systems for innovative medicines, citing concerns that current rules may disadvantage American drugmakers. The move marks a fresh escalation in transatlantic trade tensions, with Washington seeking to pressure Berlin over what it describes as restrictive pricing mechanisms affecting US-developed pharmaceuticals.